Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing.
The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.
The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.
Location: India, Gujarat, Ahmedabad
Employees: 501-1000
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | Quadria Ca... | quadriacap... |
Mentions in press and media 4
| Date | Title | Description |
| 08.08.2023 | NIIT Learning valued at Rs 5,000 cr; Concord Biotech IPO subscribed 25x | NIIT Learning valued at Rs 5,000 cr on debut Shares of NIIT Learning Systems—demerged from NIIT—finished at Rs 374 during their trading debut on Tuesday. At the last close, the company was valued at a little over Rs 5,000 crore. Click here ... |
| 31.07.2023 | Jhunjhunwala-backed Concord Biotech eyes to raise Rs 1,550 cr through IPO | Ahmedabad-based Concord Biotech, makers of fermentation-based bulk drugs, is aiming to raise between Rs 1,475.26 crore and Rs 1,550.59 crore from an initial public offering (IPO) set to open on Friday. Rakesh Jhunjhunwala-backed Concord Bio... |
| 24.12.2021 | Mahindra Homes Private Limited announces an Equity Buyback for 37,800 shares, for INR 1,101.08 million. | Mahindra Homes Private Limited announces a share repurchase program. Under the program, the company will repurchase up to 37,800 Series B and Series C equity shares for INR 1,101.08 million. The shares will be repurchased at a price of INR ... |
| 22.09.2015 | London-based PE firm Actis Capital in talks to buy minority stake in Concord Biotech | Premium London-based private equity firm Actis Capital is in discussions to buy a significant minority stake in Ahmedabad-based Concord Biotech Ltd, according to two people with knowledge of the matter. Continue reading this story with a su... |